Polaryx Therapeutics, Inc. Common Stock

Polaryx Therapeutics, Inc. Common Stock

PLYX

Get informed when a big investor buys or sells

+ Follow
Market Cap$112.2M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Polaryx Therapeutics, Inc. Common StockPolaryx Therapeutics, Inc. Common Stock-17.3--260%--
$0.11

Current Fair Value

95.4% downside

Overvalued by 95.4% based on the discounted cash flow analysis.

Share Statistics

Market cap$112.20 Million
Enterprise Value$109.12 Million
Dividend Yield$- (-)
Earnings per Share$-0.19
Beta0
Outstanding Shares47,219,329

Return

Return on Equity-260.33%ROE
Return on Assets-184.95%
Return on Invested Capital-189.99%

Valuation & Multiples

P/E Ratio-17.28P/E Ratio
PEG34.8PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-23.09
Enterprise Value to Net Income-17
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 15, 2026
EPS Estimate
$-0.02
Average shareholder expectation
Revenue Estimate
-
Average shareholder expectation

Next Earnings Call

Expected Date
September 2, 2026
EPS Estimate
$-0.03
Average shareholder expectation
Revenue Estimate
-
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %4.80%▲ 4.80%
Total Invested$17.14M
Investors Holding14▲ 14.00%

ESG Score

No data

About Polaryx Therapeutics, Inc. Common Stock

11 employees
CEO: Alex Yang

Polaryx Therapeutics, Inc., operates as a biotech company that develops small molecule therapeutics for lysosomal storage disorders and neurodegenerative disorders. Its pipeline includes PLX-100, a combination of PLX-200 and a supplement...